Last updated on August 2019

A First-In-Human Study to Evaluate Safety Tolerability Reactogenicity and Immunogenicity of JNJ-64300535 a DNA Vaccine Administered by Electroporation-Mediated Intramuscular Injection in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed


Brief description of study

The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated chronic hepatitis B (CHB) participants.

Clinical Study Identifier: NCT03463369

Find a site near you

Start Over

UK Leipzig

Leipzig, Germany
  Connect »